Acute lymphoblastic leukemia. Survival in children

Area of Science:

• Pediatric Oncology
• Clinical Hematology
• Cancer Research

Background:

• Childhood acute lymphoblastic leukemia (ALL) remains a significant challenge in pediatric oncology.
• Cooperative studies aim to improve treatment protocols and patient outcomes for ALL.
• Risk stratification is crucial for tailoring therapy in ALL patients.

Purpose of the Study:

• To evaluate the impact of the GLATHEM cooperative study on survival rates in children with ALL.
• To compare remission durations between standard and high-risk ALL patients.
• To assess the effect of levamisole on long-term remission in pediatric ALL.

Main Methods:

• A clinical study involving 80 children diagnosed with ALL.
• Patients were divided into three groups: pre-GLATHEM and two groups within the GLATHEM study.
• Survival and remission data were analyzed, with a focus on risk groups and levamisole treatment.

Main Results:

• Overall 5-year survival for ALL patients in the study was 40%, exceeding 50% for those in the GLATHEM study.
• Complete remission duration of over 6 years was significantly higher in standard-risk versus high-risk ALL patients.
• A greater proportion of children receiving levamisole maintained complete remission for 4 years or more compared to those who did not.

Conclusions:

• The GLATHEM cooperative study has demonstrated improved survival outcomes for childhood ALL.
• Risk stratification is a key factor influencing long-term remission in ALL.
• Levamisole may be a beneficial adjuvant therapy for maintaining remission in pediatric ALL patients.